CIAS
CRBP icon

Capital Investment Advisory Services’s Corbus Pharmaceuticals CRBP Stock Holding History

Capital Investment Advisory Services’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-23
Closed -$3K – 698
2019
Q3 		$3K Hold
23
– – ﹤0.01% 1201
2019
Q2 		$4K Hold
23
– – ﹤0.01% 1167
2019
Q1 		$5K Buy
+23
New +$5.07K ﹤0.01% 963

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Capital Investment Advisory Services's CRBP Position: Q4 2019 in Review

Capital Investment Advisory Services sold out of Corbus Pharmaceuticals (CRBP) in Q4 2019, closing a stake of 23 shares — an estimated $3K sold.

Capital Investment Advisory Services first reported a position in CRBP in Q1 2019 and held it in 3 quarters. The position peaked at $5K in Q1 2019. 105 funds tracked by Wall St. Rank hold CRBP as of Q4 2019.

  • Capital Investment Advisory Services reported no remaining Corbus Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 23 Corbus Pharmaceuticals shares in Q4 2019, an estimated $3K.
  • Capital Investment Advisory Services first reported a position in Corbus Pharmaceuticals in Q1 2019 and held it in 3 quarters.
  • Capital Investment Advisory Services's Corbus Pharmaceuticals position peaked at $5K in Q1 2019.
  • 105 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2019.

Based on Capital Investment Advisory Services's 13F filing for Q4 2019, filed 4 Feb 2020.